Paulo Rangel is the Chief Business Officer and cofounder of Primmune and brings 25 years of experience in the pharmaceutical and related industries in both small and large companies. Before Primmune, Mr. Rangel was President, CEO, and cofounder of Evince Biosciences, a precursor to Primmune Therapeutics. Before Evince, Mr. Rangel was a partner at ProPharma Partners International, an international consulting group. He concentrated on working with biopharmaceutical and medical device companies on worldwide in- and out-licensing, valuations, business plans, and market research. Before ProPharma, Mr. Rangel was Head of Global Business Development at Besins Healthcare, a global pharmaceutical company with products targeted for women’s and men’s health. Mr. Rangel was a founder of, and key executive in, two medical device start-ups, Lasercure Sciences and 5i Sciences (now Sommetrics). In those positions, he completed the financing, clinical studies, and collaborations and was responsible for all intellectual property. Mr. Rangel has filled key roles in a number of other biotechnology companies and worked at Amgen and Hybritech/Lilly early in his career. Mr. Rangel received a B.A. in chemistry and biochemistry from UC San Diego and an MBA from Duke University’s Fuqua School of Business.
Paulo Rangel
